Liao, C.-Y.; Gonzalez-Ferrer, C.; Whipple, S.; Peterson, P.M.; Barker, S.S.; Bhandari, N.R.; Wang, F.
Real-World Outcomes of Selective RET Inhibitor Selpercatinib in the United States: Descriptive, Retrospective Findings from Two Databases. Cancers 2024, 16, 3835.
https://doi.org/10.3390/cancers16223835
AMA Style
Liao C-Y, Gonzalez-Ferrer C, Whipple S, Peterson PM, Barker SS, Bhandari NR, Wang F.
Real-World Outcomes of Selective RET Inhibitor Selpercatinib in the United States: Descriptive, Retrospective Findings from Two Databases. Cancers. 2024; 16(22):3835.
https://doi.org/10.3390/cancers16223835
Chicago/Turabian Style
Liao, Chi-Yin, Carmen Gonzalez-Ferrer, Samuel Whipple, Patrick M. Peterson, Scott S. Barker, Naleen Raj Bhandari, and Feng Wang.
2024. "Real-World Outcomes of Selective RET Inhibitor Selpercatinib in the United States: Descriptive, Retrospective Findings from Two Databases" Cancers 16, no. 22: 3835.
https://doi.org/10.3390/cancers16223835
APA Style
Liao, C. -Y., Gonzalez-Ferrer, C., Whipple, S., Peterson, P. M., Barker, S. S., Bhandari, N. R., & Wang, F.
(2024). Real-World Outcomes of Selective RET Inhibitor Selpercatinib in the United States: Descriptive, Retrospective Findings from Two Databases. Cancers, 16(22), 3835.
https://doi.org/10.3390/cancers16223835
